Stem And Prot On Pennytobuck.com's Stock Watchlist
PROTEONOMIX, INC
PROTEONOMIX, INC. (OTCBB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.
Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the PROT investment opportunity to institutional investors.
The trip is scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.).
Mr. Cohen will also discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.
In their release from August 17th, 2010, their recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC., a Nevis Island limited liability company.
Mr. Michael Cohen stated, "Proteonomix has made great strides recently and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships."
PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix's operating subsidiary. For More Information On PROT visit http://www.proteonomix.com/
StemCells, Inc. (Nasdaq:STEM) announced the publication of new preclinical data demonstrating STEM's proprietary human neural stem cells restore lost motor function in mice with chronic spinal cord injury.
This is the first published study to show that human neural stem cells can restore mobility even when administered at time points beyond the acute phase of trauma, suggesting the prospect of treating a much broader population of injured patients than previously demonstrated.
This groundbreaking study, entitled "Human Neural Stem Cells Differentiate and Promote Locomotor Recovery in an Early Chronic Spinal Cord Injury NOD-scid Mouse Model," was led by Dr. Aileen Anderson of the Sue and Bill Gross Stem Cell Research Center at the University of California, Irvine (UCI). The paper was published yesterday in the international peer-reviewed journal PLoS ONE, and is available online at http://dx.plos.org/10.1371/journal.pone.0012272.
In this latest study, StemCells' human neural stem cells were transplanted into mice 30 days after a spinal cord injury that results in hind limb paralysis. The transplanted mice demonstrated a significant and persistent recovery of walking ability in two separate tests of motor function when compared to control groups. These results are particularly significant because it is the first time that human neural stem cells have been shown to promote functional recovery in a chronic spinal cord injury setting, which is characterized as a point in time after injury in which inflammation has stabilized and behavioral recovery has reached a plateau. In humans, the chronic phase typically does not set in until several weeks or months following the injury.
Aileen Anderson, Ph.D., Associate Professor in the Departments of Physical Medicine and Rehabilitation, and Anatomy and Neurobiology at UCI, added, "Human neural stem cells are a novel therapeutic approach that holds much promise for spinal cord injury. However, published research to date has generally focused on the acute and sub-acute phases. As part of our long-standing collaboration with StemCells, we have pursued a thoughtful and deliberate research strategy to establish the groundwork necessary to advance this cell-based approach into the clinic. This latest study builds on the extensive work we had previously published in the sub-acute phase of injury, and offers additional hope to those who are paralyzed or have impaired motor function."
STEM is engaged in the research, development, and commercialization of stem cell therapeutics and tools for use in stem cell-based research and drug discovery. In its therapeutic product development programs, StemCells is targeting diseases of the central nervous system and liver. StemCells' lead product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children. StemCells also markets specialty cell culture products under the SC Proven(R) brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about STEM is available at www.stemcellsinc.com.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)
by: Bill Pennyman
Stock Update On Gg,nsu, Orfg From Pennytobuck.com Stock Highlight On Taxs, Cs, Etfc From Pennytobuck.com Be Calm And Have Fun At The Glorious Cities At Eastern Aegean For Your Most Wonderful Greece Breaks Loosen Up And Luxuriate In At These Delightful Places In Olympia For Your Once In A Lifetime Land Of The Draenei and Blood Elves Get The Best Massage And Remedy Cramps Faster Tell You The Basic Use Of Cold Room And Axial Fan Feel Quiet And Delight In At These Pleasing Villages In Olympia For Your Most Wonderful Greek Visits Get the length and size that you want with X4 Extender Be Calm And Have Fun At The Wondrous Areas At Meteora For Your Most Wonderful Land Of The Gods Visit Oil and Gas Supply Asia Pacific Main Features of a Search Grant and its Influence on People Lighten Up And Delight In At The Magnificent Cities In Pelion For Your Once In A Lifetime Greek Visi